US-Iran Pause Triggers Relief Rally | The Pulse 7/27/2026

Watch on YouTube ↗  |  July 27, 2026 at 13:24  |  49:32  |  Bloomberg Markets
Speakers
Guy — Anchor, Bloomberg
Anthony — Bloomberg Reporter
Deirdre — Bloomberg Reporter
Clemens Fuest — President, Ifo Institute
Subitha Subramaniam — Head of Investment Strategy, Sarasin & Partners
Tim — Global Chief Content Officer, Bloomberg

Summary

Markets rallied on a US-Iran pause that sent oil sharply lower, with Germany outperforming on energy relief. The show covered Germany's Ifo beat, ECB hike risks, CXMT's 466% IPO pop, Nvidia's data-center financing, AstraZeneca's strong pipeline, and the coming wave of big-tech earnings.

  • US-Iran halt to strikes triggers 6% drop in Brent crude and a broad relief rally in stocks and bonds.
  • German Ifo business confidence beats, with improved manufacturing expectations despite energy volatility.
  • Ifo President Clemens Fuest sees slow German recovery below 1%, driven by government spending, and backs an ECB rate hike.
  • Chief economist Subitha Subramaniam warns volatility taxes growth, sees bond-market fragmentation, and thinks the Fed is underestimating neutral rates.
  • China's CXMT surges 466% on Shanghai debut; the IPO is described as deliberately underpriced amid AI boom.
  • AstraZeneca beats profit expectations, reaffirms confidence in its $80bn 2030 revenue target, and highlights a growing oncology and obesity pipeline.
  • Big week ahead: four Mega-cap tech earnings, plus key memory chip results from Samsung and SK Hynix, seen as critical for the AI trade.
  • M&A surges to $2.6tn in H1 on a megadeal conviction cycle, with Europe more open to big strategic deals.
Ideas
Guy Anchor, Bloomberg 1:28
Lower oil boosts German equities.
The US-Iran pause is driving a sharp drop in oil, providing relief to energy-intensive Europe; Germany, as the most energy-dependent major economy, is the biggest beneficiary and is strongly outperforming equity peers.
Anthony Bloomberg Reporter 25:51
CXMT underpriced, AI boom continues.
CXMT's massive IPO pop reflects intentional underpricing of Chinese AI chip listings; the stock is not priced for perfection and fits a pattern of large listing gains as China funds its AI expansion, suggesting continued upside.
Deirdre Bloomberg Reporter 31:10
AstraZeneca pipeline drives confidence.
AstraZeneca's strong oncology pipeline and obesity assets make its $80B 2030 revenue target easily achievable, and management is confident on post-2030 growth, reassuring the market and supporting the stock.
Up Next

This Bloomberg Markets video, published July 27, 2026, features Guy, Anthony, Deirdre discussing DAX, CXMT, AZN. 3 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Guy, Anthony, Deirdre  · Tickers: DAX, CXMT, AZN